Naim Rashid Archives - UNC Lineberger Comprehensive Cancer Center

Pink ribbon with research tools on a pink table.

A new clinical trial that adjusts treatment as breast cancer evolves is now open and enrolling patients at UNC Lineberger Comprehensive Cancer Center.

Cluster of circulating tumor cells and white blood cells.

UNC Lineberger will lead the development of a next-generation clinical trial for metastatic breast cancer. The new trial design will adapt treatment plans in near real-time by analyzing changes in each patient’s cancer and matching it to the most promising therapy.

Naim Rashid, PhD, has received a Department of Defense Pancreatic Cancer Research Program pilot award to build an AI tool that generates personalized clinical trial recommendations for patients with PDAC.

Human colon cancer cells with the cell nuclei stained red and the protein E-cadherin stained green. E-cadherin is a cell adhesion molecule and its loss signals a process known as the epithelial-mesenchymal transition in which cells acquire the ability to migrate and become invasive.

“To our knowledge, this is the first prospective trial to look at gene mutations using state-of-the-art gene sequencing in this population,” said study author and UNC Lineberger member Naim Rashid, PhD.

The San Antonio Breast Cancer Symposium features presentations outlining basic, translational, clinical and community-based study findings focused on advancing the prevention, diagnosis and treatment of breast cancer.

Lisa M. Carey, MD, ScM, FASCO, Charles M. Perou, PhD, and Aranzazu Fernandez-Martinez, MD, PhD

Researchers report specific immune system cells can help them determine whether HER2-positive breast cancer will respond to treatment.

The National Cancer Institute has awarded the UNC Lineberger Pancreatic Cancer Center of Excellence a five-year, $10.9 million Pancreatic Cancer Specialized Program of Research Excellence (SPORE) grant.

Headshots of Matthew Flick, Naim Rashid, and Jen Jen Yeh

The NCI awarded $9.3 million in support of two five-year research projects from researchers in the UNC Lineberger Pancreatic Cancer Center of Excellence in partnership with other institutions.

UNC Lineberger’s Yuliya Pylayeva-Gupta, PhD, was the corresponding author of a paper published in Cell Reports Medicine that examined how B cells might be reprogrammed to improve anti-tumor immune response in pancreatic cancer. The study was led by a former research associate, Rahul Mirlekar.

Researchers at the University of North Carolina and North Carolina State University have developed a computational framework to generate evidence-based optimal cancer treatment decisions informed by a patient’s genomic biomarkers.

Tag: Naim Rashid

A new clinical trial for metastatic breast cancer opens

UNC Lineberger awarded up to $28M to develop an adaptive clinical trial for metastatic breast cancer

Rashid awarded grant to develop AI tool that recommends optimal clinical trials to pancreatic cancer patients

Study finds Black patients with metastatic colorectal cancer have distinctly different gene mutations than white patients

Cancer center researchers to present latest findings at international breast cancer meeting

Immune system B-cells can help predict HER2-positive breast cancer treatment response

UNC Lineberger pancreatic cancer therapy studies backed by 5-year, $10.9 million NIH SPORE grant

UNC Lineberger pancreatic cancer researchers receive five-year, $4.6 million grants from National Cancer Institute

Pylayeva-Gupta published in Cell Reports Medicine

Study shows new machine learning method may lead to optimal cancer treatment decisions